SG11201504447XA - Novel pharmaceutical formulations and their use in the treatment of periodontal disease - Google Patents
Novel pharmaceutical formulations and their use in the treatment of periodontal diseaseInfo
- Publication number
- SG11201504447XA SG11201504447XA SG11201504447XA SG11201504447XA SG11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA SG 11201504447X A SG11201504447X A SG 11201504447XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- pharmaceutical formulations
- periodontal disease
- novel pharmaceutical
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1222455.6A GB201222455D0 (en) | 2012-12-13 | 2012-12-13 | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
PCT/GB2013/053283 WO2014091239A1 (en) | 2012-12-13 | 2013-12-13 | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201504447XA true SG11201504447XA (en) | 2015-07-30 |
Family
ID=47630648
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201704712QA SG10201704712QA (en) | 2012-12-13 | 2013-12-13 | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
SG11201504447XA SG11201504447XA (en) | 2012-12-13 | 2013-12-13 | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201704712QA SG10201704712QA (en) | 2012-12-13 | 2013-12-13 | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
Country Status (11)
Country | Link |
---|---|
US (2) | US10471058B2 (en) |
EP (2) | EP3498290A1 (en) |
JP (2) | JP6441809B2 (en) |
KR (1) | KR20150095795A (en) |
CN (1) | CN104884075B (en) |
CA (1) | CA2893935C (en) |
DK (1) | DK2931299T3 (en) |
ES (1) | ES2718499T3 (en) |
GB (2) | GB201222455D0 (en) |
SG (2) | SG10201704712QA (en) |
WO (1) | WO2014091239A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9890198B2 (en) | 2010-12-03 | 2018-02-13 | S&T Global Inc. | Cyclosporin derivatives and uses thereof |
GB201410869D0 (en) * | 2014-06-18 | 2014-07-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontal disease |
CA3095307A1 (en) * | 2018-03-27 | 2019-10-03 | Dentsply Sirona Inc. | Methods of treatment of the dental pulp and filling root canals using anti inflammatory rinse solution and filling composition |
WO2020037530A1 (en) * | 2018-08-22 | 2020-02-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Crystalline form of compound and uses thereof in medicine |
US11845809B2 (en) * | 2018-12-14 | 2023-12-19 | Waterstone Pharmaceuticals(Wuhan) Co., Ltd. | Maleate of SCY-635 and uses thereof in medicine |
BR112022018929A2 (en) * | 2020-03-26 | 2022-12-06 | Farsight Medical Tech Shanghai Co Ltd | CYCLOPHILIN INHIBITORS AND THEIR USES |
JP7144703B2 (en) | 2020-09-30 | 2022-09-30 | ダイキン工業株式会社 | Three-dimensional modeling composition and three-dimensional modeled object |
KR102640323B1 (en) * | 2021-11-30 | 2024-02-27 | 대우제약 주식회사 | Stable nanosuspension of cyclosporine |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0597697A (en) * | 1991-10-02 | 1993-04-20 | Lion Corp | Alveolar bone-regenerating agent |
EP0708646A1 (en) * | 1994-05-06 | 1996-05-01 | Alcon Laboratories, Inc. | Use of vitamin e tocopheryl derivatives in ophthalmic compositions |
HU215966B (en) * | 1994-11-21 | 1999-07-28 | BIOGAL Gyógyszergyár Rt. | Oral multiple emulsion-preconcentrate containing cyclosporin |
US5565188A (en) * | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
SE9601421D0 (en) * | 1996-04-12 | 1996-04-12 | Astra Ab | New composition |
US5891845A (en) * | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
DE19932157A1 (en) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Process for the gentle production of ultra-fine microparticles and nanoparticles |
AR036853A1 (en) * | 2001-10-19 | 2004-10-06 | Isotechnika Inc | CYCLOSPORINE ANALOG BLENDS AND ITS USE AS IMMUNOMODULATING AGENTS. |
MEP89008A (en) * | 2001-10-19 | 2011-12-20 | Novel cyclosporin analog microemulsion preconcentrates | |
US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
EP1510206A1 (en) * | 2003-08-29 | 2005-03-02 | Novagali Pharma SA | Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
WO2005072701A1 (en) * | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US20050277584A1 (en) * | 2004-06-09 | 2005-12-15 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
CN101048137A (en) * | 2004-10-29 | 2007-10-03 | 诺瓦提斯公司 | Spontaneously dispersible pharmaceutical compositions |
CA2598204C (en) * | 2004-11-09 | 2015-01-13 | Board Of Regents, The University Of Texas System | Stabilized hme composition with small drug particles |
MX2007012762A (en) * | 2005-04-12 | 2008-01-14 | Elan Pharma Int Ltd | Nanoparticulate and controlled release compositions comprising cyclosporine. |
JP5449775B2 (en) * | 2005-10-19 | 2014-03-19 | チャバフ ピーティーワイ エルティーディー | Reduction of side effects with aromatase inhibitors used to treat breast cancer |
KR20080065704A (en) * | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | Methods, compositions, and kits for the treatment of medical conditions |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
CN101032620B (en) * | 2007-03-08 | 2010-05-19 | 上海凯昭医药科技有限公司 | Cyclosporine emulsion and the preparing method |
DE102008062373A1 (en) * | 2007-12-21 | 2009-06-25 | Essiger, Holger, Dr. | Agent comprising at least one active ingredient having gum-growth activity |
UA102414C2 (en) * | 2008-11-06 | 2013-07-10 | Дебио Решерш Фармасьютик С.А. | Cycloundecadepsipeptide compounds for treating hepatitis c infections |
KR100924236B1 (en) * | 2009-06-23 | 2009-10-29 | 충남대학교산학협력단 | Methods and apparatus for preparing ultra-fine particles with narrow particle size distribution |
CN102085295B (en) * | 2009-12-08 | 2012-09-05 | 华中科技大学 | Nano-emulsion pharmaceutical composition containing spring onion extract for oral mucosa administration and preparation method thereof |
IT1404931B1 (en) * | 2010-06-11 | 2013-12-09 | Medivis S R L | OPHTHALMIC COMPOSITIONS FOR THE ADMINISTRATION OF LIPO-SOLUBLE ACTIVE PRINCIPLES. |
WO2012051194A1 (en) * | 2010-10-12 | 2012-04-19 | Allergan, Inc. | Cyclosporin analogs |
AU2012262513B2 (en) * | 2011-05-27 | 2016-03-17 | Allergan, Inc. | A crystalline form of cyclosporine A, methods of preparation, and methods for use thereof |
-
2012
- 2012-12-13 GB GBGB1222455.6A patent/GB201222455D0/en not_active Ceased
-
2013
- 2013-12-13 KR KR1020157018368A patent/KR20150095795A/en not_active Application Discontinuation
- 2013-12-13 CA CA2893935A patent/CA2893935C/en active Active
- 2013-12-13 SG SG10201704712QA patent/SG10201704712QA/en unknown
- 2013-12-13 EP EP19155292.6A patent/EP3498290A1/en not_active Withdrawn
- 2013-12-13 EP EP13808188.0A patent/EP2931299B1/en active Active
- 2013-12-13 WO PCT/GB2013/053283 patent/WO2014091239A1/en active Application Filing
- 2013-12-13 JP JP2015547146A patent/JP6441809B2/en active Active
- 2013-12-13 CN CN201380068765.2A patent/CN104884075B/en active Active
- 2013-12-13 DK DK13808188.0T patent/DK2931299T3/en active
- 2013-12-13 GB GB1511770.8A patent/GB2523707A/en not_active Withdrawn
- 2013-12-13 ES ES13808188T patent/ES2718499T3/en active Active
- 2013-12-13 SG SG11201504447XA patent/SG11201504447XA/en unknown
- 2013-12-13 US US14/651,165 patent/US10471058B2/en active Active
-
2018
- 2018-11-21 JP JP2018217906A patent/JP6608028B2/en active Active
-
2019
- 2019-10-02 US US16/591,202 patent/US20200085825A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GB2523707A (en) | 2015-09-02 |
CA2893935C (en) | 2021-11-02 |
US10471058B2 (en) | 2019-11-12 |
US20200085825A1 (en) | 2020-03-19 |
JP2016504314A (en) | 2016-02-12 |
WO2014091239A1 (en) | 2014-06-19 |
CN104884075A (en) | 2015-09-02 |
GB201222455D0 (en) | 2013-01-30 |
JP2019048860A (en) | 2019-03-28 |
GB201511770D0 (en) | 2015-08-19 |
CN104884075B (en) | 2018-04-03 |
EP2931299B1 (en) | 2019-02-06 |
JP6441809B2 (en) | 2018-12-19 |
US20150313959A1 (en) | 2015-11-05 |
JP6608028B2 (en) | 2019-11-20 |
SG10201704712QA (en) | 2017-07-28 |
EP3498290A1 (en) | 2019-06-19 |
CA2893935A1 (en) | 2014-06-19 |
KR20150095795A (en) | 2015-08-21 |
DK2931299T3 (en) | 2019-04-23 |
ES2718499T3 (en) | 2019-07-02 |
EP2931299A1 (en) | 2015-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181364T8 (en) | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof | |
IL231536A (en) | Indazole-3-carboxamides , pharmaceutical compositions comprising them and their use in the treatment of diseases | |
HK1209100A1 (en) | N-substituted benzamides and their use in the treatment of pain n- | |
PL2928484T3 (en) | Compounds useful in the treatment and/or care of the skin, hair and/or mucous membranes and their cosmetic or pharmaceutical compositions | |
IL236221A (en) | Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases | |
IL237369A0 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
SG11201504447XA (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
IL232256A0 (en) | Novel purine derivatives and their use in the treatment of disease | |
HK1199401A1 (en) | Pharmaceutical formulations and the use thereof for the treatment of peanut allergy | |
HK1199712A1 (en) | 18-methyl-6,7-methylene-3-oxo-17-pregn-4-ene-21,17-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis 18--67--3--17--4--2117- | |
IL271352B (en) | Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases | |
HK1203947A1 (en) | Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions (halofuginol) | |
GB2515439B (en) | Vesicular formulations for use in the treatment of reduced mobility | |
IL233875A (en) | Composition and use thereof in the treatment of anal rhagades | |
ZA201402452B (en) | Novel pyrimethanil formulations and uses thereof in the treatment of crops | |
GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
IL234093A0 (en) | Oral unit dosage forms and uses of same for the treatment of gaucher disease | |
HK1214771A1 (en) | Formulations for use in the treatment of skin conditions | |
HK1206598A1 (en) | Eprotirome for use in the prevention and or treatment of hair disorders and compositions thereof | |
GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
SI2537528T1 (en) | Pharmaceutical compositions containing beta- and alpha-galactosidase and their use in the treatment of gastroesophageal reflux disease |